All Updates

All Updates

icon
Filter
Partnerships
Oxford Biodynamics partners with KCL to enhance rheumatoid arthritis treatment using EpiSwitch technology
Precision Medicine
May 16, 2024
This week:
Funding
GrayMatter Robotics raises USD 45 million in Series B funding to accelerate AI-powered robotics solutions
Smart Factory
Jun 20, 2024
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Logistics Tech
Jun 20, 2024
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Smart Factory
Jun 20, 2024
Funding
FairNow raises USD 3.5 million to advance AI governance solutions
Generative AI Infrastructure
Jun 20, 2024
Partnerships
Gravitics develops testing gauntlet for larger spacecraft in collaboration with NASA
Space Travel and Exploration Tech
Jun 20, 2024
M&A
knownwell acquires Alfie Health to integrate AI in primary and obesity care services
Telehealth
Jun 20, 2024
Funding
Pomelo Care raises USD 46 million in Series B funding to expand virtual maternal care
Telehealth
Jun 20, 2024
Funding
Isar Aerospace raises EUR 65 million, backed by NATO Innovation Fund
Space Travel and Exploration Tech
Jun 20, 2024
Product updates
Beyond Meat releases new Beyond Sausage, expanding its Beyond IV product line
Plant-based Meat
Jun 20, 2024
Product updates
Funding
SurrealDB raises USD 20 million in Series A; launches beta version of Surreal Cloud
Data Infrastructure & Analytics
Jun 20, 2024
Precision Medicine

Precision Medicine

May 16, 2024

Oxford Biodynamics partners with KCL to enhance rheumatoid arthritis treatment using EpiSwitch technology

Partnerships

  • Oxford Biodynamics (OBD) has partnered with King's College London to leverage the EpiSwitch technology in rheumatoid arthritis (RA) treatment, following a successful APIPPRA trial for Abatacept, a biological therapy used to treat arthritis by targeting the cause of inflammation.

  • Using OBD’s proprietary EpiSwitch platform, the collaboration aims to identify patients at high risk of having RA who can benefit from the therapeutics of Abatacept. EpiSwitch is an epigenetic platform that can identify and validate biomarkers for various diseases, including cancer and autoimmune and neurodegenerative conditions. The APIPPRA trial had reportedly shown positive results, with 92.8% of patients who received Abatacept therapy remaining RA-free after a year. 

  • Oxford BioDynamics is a UK-based biotechnology company that develops precision medicine tests through its proprietary EpiSwitch 3D genomics platform. This platform allows the creation of molecular diagnostic classifiers for a range of applications, including drug response prediction, diagnosis, and patient prognosis. OBD’s key products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test) for predicting cancer immunotherapy responses, EpiSwitch PSE (Prostate Screening Test), EpiSwitch CST (Covid Severity Test), and EpiSwitch Explorer for 3D genome profiling.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.